Evidence map›Paper›PMID 38863623›Full record

ArticleFrontiers in oncology2024

Dissection of the signal transduction machinery responsible for the lysyl oxidase-like 4-mediated increase in invasive motility in triple-negative breast cancer cells: mechanistic insight into the integrin-β1-NF-κB-MMP9 axis.

Fan Jiang, Youyi Chen, Nahoko Tomonobu, Rie Kinoshita, Ni Luh Gede Yoni Komalasari, Carlos Ichiro Kasano-Camones, Kazumi Ninomiya, Hitoshi Murata, Ken-Ichi Yamamoto, Yuma Gohara and 13 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Fan Jiang *Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Youyi Chen *Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Nahoko TomonobuDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Rie KinoshitaDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Ni Luh Gede Yoni KomalasariFaculty of Medicine, Udayana University, Denpasar, Bali, Indonesia.
Carlos Ichiro Kasano-CamonesFaculty of Science and Technology, Division of Molecular Science, Gunma University, Kiryu, Gunma, Japan.
Kazumi NinomiyaFaculty of Science and Technology, Division of Molecular Science, Gunma University, Kiryu, Gunma, Japan.
Hitoshi MurataDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Ken-Ichi YamamotoDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yuma GoharaDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Toshiki OchiDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
I Made Winarsa RumaFaculty of Medicine, Udayana University, Denpasar, Bali, Indonesia.
I Wayan SumardikaFaculty of Medicine, Udayana University, Denpasar, Bali, Indonesia.
Jin ZhouMedical Oncology Department of Gastrointestinal Tumors, Liaoning Cancer Hospital & Institute, Cancer Hospital of the Dalian University of Technology, Shenyang, Liaoning, China.
Tomoko HonjoDepartment of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.
Yoshihiko SakaguchiDepartment of Microbiology, Tokushima Bunri University, Sagamihara, Tokushima, Japan.
Akira YamauchiDepartment of Biochemistry, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Futoshi KuribayashiDepartment of Biochemistry, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Junichiro FutamiDepartment of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.
Eisaku KondoDivision of Tumor Pathology, Near InfraRed Photo-Immuno-Therapy Research Institute, Kansai Medical University, Osaka, Japan.
Yusuke InoueFaculty of Science and Technology, Division of Molecular Science, Gunma University, Kiryu, Gunma, Japan.
Shinichi ToyookaDepartment of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Masakiyo SakaguchiDepartment of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) cells are a highly formidable cancer to treat. Nonetheless, by continued investigation into the molecular biology underlying the complex regulation of TNBC cell activity, vulnerabilities can be exposed as potential therapeutic targets at the molecular level. We previously revealed that lysyl oxidase-like 4 (LOXL4) promotes the invasiveness of TNBC cells via cell surface annexin A2 as a novel binding substrate of LOXL4, which promotes the abundant localization of integrin-β1 at the cancer plasma membrane. However, it has yet to be uncovered how the LOXL4-mediated abundance of integrin-β1 hastens the invasive outgrowth of TNBC cells at the molecular level. Methods: LOXL4-overexpressing stable clones were established from MDA-MB-231 cells and subjected to molecular analyses, real-time qPCR and zymography to clarify their invasiveness, signal transduction, and matrix metalloprotease (MMP) activity, respectively. Results: Our results show that LOXL4 potently promotes the induction of matrix metalloprotease 9 (MMP9) via activation of nuclear factor-κB (NF-κB). Our molecular analysis revealed that TNF receptor-associated factor 4 (TRAF4) and TGF-β activated kinase 1 (TAK1) were required for the activation of NF-κB through Iκβ kinase kinase (IKKα/β) phosphorylation. Conclusion: Our results demonstrate that the newly identified LOXL4-mediated axis, integrin-β1-TRAF4-TAK1-IKKα/β-Iκβα-NF-κB-MMP9, is crucial for TNBC cell invasiveness.

Indexed as

breast cancerinvasionlysyl oxidaseMMP9NF-κB

Identifiers

PMID38863623
PMCPMC11165029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.